Tag Archive for: Vaccines

The U.S. government is nearing an agreement to fund a late-stage trial of Moderna’s mRNA pandemic bird flu vaccine, the Financial Times reported on Thursday, as an H5N1 outbreak spreads through egg farms and among cattle herds.

The sale will allow GSK to sharpen its focus on vaccines, cancer and infectious diseases, which are part of CEO Emma Walmsley’s plans to boost earnings at the drugmaker.

CEO Emma Walmsley’s strategy has focussed on vaccines, cancer and infectious diseases and a shift in the company’s HIV focus to long-acting treatment and prevention therapies. The strategy has paid off as GSK gears up for 12 launches from 2025.

According to Repertoire, the deal will use its Decode discovery platform to find the vaccine candidates. Decode is a T cell receptor-epitope platform using proprietary lipid nanoparticle delivery technology. The biotech said that the vaccines will aim to treat the underlying causes by “resetting” the immune system.

Though a Sanofi spokesperson declined to provide details about the operations overhaul, including its timeline, scope and the number of employees that will be terminated, they said that the changes are part of Sanofi’s push to implement “a streamlined strategic sales structure.”

The U.S. Centers for Disease Control and Prevention (CDC) issued a health advisory urging people, particularly children and international travelers, to get vaccinated against measles due to the increase in cases this year.

The CEO of the world’s biggest vaccine maker, Serum Institute of India, said the company has bolstered its manufacturing ahead of launches over the next few years of shots against diseases like malaria and dengue by repurposing facilities used to make COVID-19 immunizations.

The company’s planned investment includes 450 million pounds to research, develop and manufacture vaccines at its manufacturing site in Speke, Liverpool, and another 200 million pounds to expand its existing presence in Cambridge, where its global headquarters are located.

The biopharma industry has been largely underfunding vaccine development despite its strong potential to prevent diseases and reduce hospitalizations and deaths, according to a report published by industry advocacy group Biotechnology Innovation Organization.

The British drugmaker said it sold around 300 million shares of Haleon, cutting its shareholding to 4.2%, as it expands its portfolio of specialty medicines.